Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
167.3 USD | -0.30% | +1.60% | +7.95% |
Apr. 25 | Cigna to offer Humira rivals with $0 copay at specialty pharmacy | RE |
Apr. 25 | AbbVie Says Rinvoq Shows Superiority Versus Dupixent in Atopic Dermatitis Trial Primary Endpoint | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.95% | 296B | |
+24.90% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+13.21% | 233B | |
+5.51% | 201B | |
-10.22% | 193B | |
-12.26% | 143B | |
-6.47% | 144B | |
+0.95% | 123B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Piper Sandler Adjusts Price Target on AbbVie to $157 From $155, Maintains Overweight Rating